Dutasteride significantly improves quality of life measures in patients with enlarged prostate

M. P. O'Leary, Claus Roehrborn, L. Black

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

The purpose of this study was to determine the effect of dutasteride on quality of life of men with lower urinary tract symptoms associated with enlarged prostate or benign prostatic hyperplasia (BPH) as measured by symptom problem index (SPI), BPH-specific interference with activities (BSIA), BPH-specific psychological well-being (BPWB) and BPH-specific lifestyle adaptations (BSLA). Data were derived from three randomized, double-blind studies conducted in 4325 men treated with placebo or dutasteride (0.5 mg/day). Primary analyses included changes from baseline in mean SPI, BSIA, BPWB and BSLA scores. Men treated with dutasteride showed significant improvements in SPI, BSIA, BPWB and BSLA scores compared with placebo.

Original languageEnglish (US)
Pages (from-to)129-133
Number of pages5
JournalProstate Cancer and Prostatic Diseases
Volume11
Issue number2
DOIs
StatePublished - Jun 2008

Fingerprint

Prostatic Hyperplasia
Prostate
Quality of Life
Life Style
Psychology
Placebos
Lower Urinary Tract Symptoms
Double-Blind Method
Dutasteride

ASJC Scopus subject areas

  • Oncology
  • Urology

Cite this

Dutasteride significantly improves quality of life measures in patients with enlarged prostate. / O'Leary, M. P.; Roehrborn, Claus; Black, L.

In: Prostate Cancer and Prostatic Diseases, Vol. 11, No. 2, 06.2008, p. 129-133.

Research output: Contribution to journalArticle

@article{803d08aa5cd54add9232d711b78ee43b,
title = "Dutasteride significantly improves quality of life measures in patients with enlarged prostate",
abstract = "The purpose of this study was to determine the effect of dutasteride on quality of life of men with lower urinary tract symptoms associated with enlarged prostate or benign prostatic hyperplasia (BPH) as measured by symptom problem index (SPI), BPH-specific interference with activities (BSIA), BPH-specific psychological well-being (BPWB) and BPH-specific lifestyle adaptations (BSLA). Data were derived from three randomized, double-blind studies conducted in 4325 men treated with placebo or dutasteride (0.5 mg/day). Primary analyses included changes from baseline in mean SPI, BSIA, BPWB and BSLA scores. Men treated with dutasteride showed significant improvements in SPI, BSIA, BPWB and BSLA scores compared with placebo.",
author = "O'Leary, {M. P.} and Claus Roehrborn and L. Black",
year = "2008",
month = "6",
doi = "10.1038/sj.pcan.4500990",
language = "English (US)",
volume = "11",
pages = "129--133",
journal = "Prostate Cancer and Prostatic Diseases",
issn = "1365-7852",
publisher = "Nature Publishing Group",
number = "2",

}

TY - JOUR

T1 - Dutasteride significantly improves quality of life measures in patients with enlarged prostate

AU - O'Leary, M. P.

AU - Roehrborn, Claus

AU - Black, L.

PY - 2008/6

Y1 - 2008/6

N2 - The purpose of this study was to determine the effect of dutasteride on quality of life of men with lower urinary tract symptoms associated with enlarged prostate or benign prostatic hyperplasia (BPH) as measured by symptom problem index (SPI), BPH-specific interference with activities (BSIA), BPH-specific psychological well-being (BPWB) and BPH-specific lifestyle adaptations (BSLA). Data were derived from three randomized, double-blind studies conducted in 4325 men treated with placebo or dutasteride (0.5 mg/day). Primary analyses included changes from baseline in mean SPI, BSIA, BPWB and BSLA scores. Men treated with dutasteride showed significant improvements in SPI, BSIA, BPWB and BSLA scores compared with placebo.

AB - The purpose of this study was to determine the effect of dutasteride on quality of life of men with lower urinary tract symptoms associated with enlarged prostate or benign prostatic hyperplasia (BPH) as measured by symptom problem index (SPI), BPH-specific interference with activities (BSIA), BPH-specific psychological well-being (BPWB) and BPH-specific lifestyle adaptations (BSLA). Data were derived from three randomized, double-blind studies conducted in 4325 men treated with placebo or dutasteride (0.5 mg/day). Primary analyses included changes from baseline in mean SPI, BSIA, BPWB and BSLA scores. Men treated with dutasteride showed significant improvements in SPI, BSIA, BPWB and BSLA scores compared with placebo.

UR - http://www.scopus.com/inward/record.url?scp=43549124856&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=43549124856&partnerID=8YFLogxK

U2 - 10.1038/sj.pcan.4500990

DO - 10.1038/sj.pcan.4500990

M3 - Article

C2 - 17592479

AN - SCOPUS:43549124856

VL - 11

SP - 129

EP - 133

JO - Prostate Cancer and Prostatic Diseases

JF - Prostate Cancer and Prostatic Diseases

SN - 1365-7852

IS - 2

ER -